FORT COLLINS, Colo.--(BUSINESS WIRE)--VetDC, Inc., today announced that it is presenting data on VDC-1101 at the 2012 American College of Veterinary Internal Medicine Forum. VDC-1101 is a novel anti-proliferative agent that preferentially targets lymphoid cells and works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.
The safety and efficacy of an every three-week administration schedule of single agent VDC-1101 was evaluated for the treatment of canine lymphoma in a previously completed animal study (n=21 subjects). VDC-1101 demonstrated substantial antitumor activity in dogs with both treatment-naïve and refractory lymphoma when administered on an every three-week schedule. Adverse events were generally mild to moderate and reversible.
Data will be presented on May 31st by Dr. Douglas Thamm, Associate Professor of Oncology at Colorado State University’s Flint Animal Cancer Center. “We are very encouraged by the results of this analysis, given the high unmet need for novel, effective veterinary anti-cancer agents, particularly in the refractory setting,” stated Dr. David Vail, Professor of Oncology at the University of Wisconsin-Madison School of Veterinary Medicine. “These results indicate that VDC-1101 may be a powerful and convenient new therapeutic option for treating lymphoma in companion animals.”
About VetDC, Inc. VetDC, Inc., a Colorado State University startup headquartered in Fort Collins, Colorado, is a veterinary biotechnology company focused on in-licensing, developing and commercializing novel biotechnologies to address serious unmet medical needs in companion animals. In 2011, the company secured seed funding from the Colorado Institute for Drug, Device and Diagnostic Development (CID4). For more information on VetDC, please visit www.vet-dc.com.